Cargando…
Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review
Heart failure (HF) continues to increase in prevalence, representing a significant burden to healthcare systems in the USA. Despite several established HF therapies, particularly for HF with reduced ejection fraction (HFrEF), rates of HF hospitalizations and cardiovascular (CV) mortality remain very...
Autor principal: | Jhalani, Nisha B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309138/ https://www.ncbi.nlm.nih.gov/pubmed/35699903 http://dx.doi.org/10.1007/s12325-022-02169-3 |
Ejemplares similares
-
SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021) -
Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction
por: Brownell, Nicholas K., et al.
Publicado: (2022) -
Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction
por: Mustapic, Ivona, et al.
Publicado: (2022) -
Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
por: Clemmer, John S., et al.
Publicado: (2023) -
Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction
por: Kim, Hyue Mee, et al.
Publicado: (2021)